Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcus Biosciences (RCUS) Enterprise Value (2017 - 2025)

Arcus Biosciences has reported Enterprise Value over the past 9 years, most recently at -$981.0 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$981.0 million for Q4 2025, changed 0.31% from a year ago — trailing twelve months through Dec 2025 was -$981.0 million (changed 0.31% YoY), and the annual figure for FY2025 was -$981.0 million, changed 0.31%.
  • Enterprise Value for Q4 2025 was -$981.0 million at Arcus Biosciences, down from -$831.0 million in the prior quarter.
  • Over the last five years, Enterprise Value for RCUS hit a ceiling of -$499.0 million in Q4 2021 and a floor of -$1.2 billion in Q1 2022.
  • Median Enterprise Value over the past 5 years was -$961.5 million (2023), compared with a mean of -$910.5 million.
  • Peak annual rise in Enterprise Value hit 32.95% in 2021, while the deepest fall reached 423.82% in 2021.
  • Arcus Biosciences' Enterprise Value stood at -$499.0 million in 2021, then plummeted by 102.2% to -$1.0 billion in 2022, then grew by 24.78% to -$759.0 million in 2023, then fell by 28.85% to -$978.0 million in 2024, then decreased by 0.31% to -$981.0 million in 2025.
  • The last three reported values for Enterprise Value were -$981.0 million (Q4 2025), -$831.0 million (Q3 2025), and -$911.0 million (Q2 2025) per Business Quant data.